Lymphoma

Lymphoma is a blood cancer affecting lymphocytes, a type of white blood that help the body to ght infections. The most common type of lymphoma, found in 90% of patients is non-Hodgkin lymphoma (NHL)1.

Treatments and prognosis vary signicantly depending on the lymphoma subtype; however, relapses are common across many forms and with each relapse - the return of the disease after a period of improvement.

“Relapse” unfortunately is a well-known term for people with lymphoma, and with each relapse their prognosis worsens. Patients often live in fear of their cancer returning, which has a signicant emotional and psychological impact – not just on them – but also on their families and friends.

Roche’s medicines have contributed to improving patient outcomes and advancing the treatment of lymphomas, yet there is still progress to be made to help as many patients in Australia as possible.

Two of our key focus areas are diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL). In DLBCL, we’re aimed at improving outcomes for people newly diagnosed with the disease and reducing the risk of relapse. For FL, our goal is to help patients achieve long lasting remissions, even after multiple lines of therapy, and minimise the impact treatment has on their day-to-day life.

To do this, we are working in partnership with the lymphoma community to improve treatment standards and support access initiatives at a global level to help as many people with lymphoma as possible to receive optimal care.